Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REX-001 for Ischemic Rest Pain in CLI and DM
NCT03111238Phase 3Terminated
- Sponsor
- Ixaka
- Start
- Apr 2017
- Primary completion
- Mar 2021
- Modality
- Stem Cell Therapies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in critical limb ischemia (CLI) comparing REX-001 Arm with Placebo Arm (2 arms). Primary endpoint: Complete relief of ischemic rest pain without developing ischemic lesions on the index leg at 12 months. Started Apr 2017; status: terminated.
02
Drugs
rexmyelocel-T
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT03111238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111238.